Tewksbury, MA - April 20, 2006 - Mitralign Inc., a privately held medical device company, has received an investment from Triathlon Medical Ventures.

Combining surgical precision with interventional therapy, Mitralign is actively developing a percutaneous solution for the treatment of mitral valve regurgitation. Mitral regurgitation is common in patients with congestive heart failure, a disease affecting 25 Million worldwide. Clinical studies have proven that mitral regurgitation significantly increases the risk of mortality in these patients. This approach will provide a catheter-based alternative to open heart surgery.

Triathlon joins Mitralign's existing investors Oxford Bioscience Partners, ABN AMRO, Giza Ventures and Accelerated Technologies.

"We are pleased to have Triathlon support our vision of enabling earlier interventional options for these patients and the physicians that treat them", commented Mitralign CEO John MacMahon.

Triathlon Medical Ventures, Managing Partner, Carrie Bates has joined Mitralign's Board of Directors. Triathlon is a Midwest-based venture capital firm that invests exclusively in the life sciences. They provide equity capital to early and expansion stage companies with proprietary biomedical technology platforms or products addressing significant human healthcare needs. They are headquartered in Cincinnati, with offices and partners in Indianapolis, Louisville and St. Louis.